MIRA Pharmaceuticals
MIRA
24 hedge funds and large institutions have $1.28M invested in MIRA Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 6 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 1
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
60% more funds holding
Funds holding: 15 → 24 (+9)
18% more capital invested
Capital invested by funds: $1.08M → $1.28M (+$199K)
1.16% more ownership
Funds ownership: 5.62% → 6.78% (+1.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$154K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$128K |
| 3 |
VF
Virtu Financial
New York
|
+$82.8K |
| 4 |
State Street
Boston,
Massachusetts
|
+$64.1K |
| 5 |
Renaissance Technologies
New York
|
+$59.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SEM
Suncoast Equity Management
Tampa,
Florida
|
-$88K |
| 2 |
LPL Financial
San Diego,
California
|
-$65K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$54.5K |
| 4 |
Millennium Management
New York
|
-$52.9K |
| 5 |
APP
Avantax Planning Partners
Dubuque,
Iowa
|
-$41.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SSA
26
Schonfeld Strategic Advisors
New York
| – | -$54.5K | -41,900 | Closed |
|
|
27
Millennium Management
New York
| – | -$52.9K | -40,725 | Closed |
|
|
APP
28
Avantax Planning Partners
Dubuque,
Iowa
| – | -$41.6K | -32,000 | Closed |
|
29
Jane Street
New York
| – | -$15.8K | -12,186 | Closed |
|
|
CSPIA
30
Cary Street Partners Investment Advisory
Richmond,
Virginia
| – | -$13K | -10,000 | Closed |
|
MIRA Hedge Fund Activity: Q4 2024 in Review
24 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in MIRA Pharmaceuticals (MIRA) for Q4 2024, worth a combined $1.28M — up 18% from $1.08M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new MIRA positions and 6 closed out — a net gain of 9 holders — while 5 added to existing stakes and 1 trimmed.
The largest buyer was Vanguard Group, opening a new position worth an estimated $154K. The largest seller was Suncoast Equity Management, cutting an estimated $88K.
- 24 institutional investors held MIRA Pharmaceuticals (MIRA) as of Q4 2024, up from 15 in Q3 2024.
- Funds reported $1.28M of MIRA Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
- 15 funds opened new MIRA Pharmaceuticals positions in Q4 2024 and 6 closed out, a net change of +9 holders.
- The largest MIRA Pharmaceuticals buyer in Q4 2024 was Vanguard Group, an estimated $154K added.
- The largest MIRA Pharmaceuticals seller in Q4 2024 was Suncoast Equity Management, an estimated $88K sold.
Based on aggregated 13F filings for Q4 2024.